Immunome (NASDAQ:IMNM) Insider Purchases $204,900.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) insider Philip Tsai purchased 10,000 shares of the firm’s stock in a transaction on Friday, December 19th. The shares were acquired at an average cost of $20.49 per share, for a total transaction of $204,900.00. Following the completion of the acquisition, the insider owned 43,300 shares of the company’s stock, valued at approximately $887,217. This trade represents a 30.03% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Immunome Price Performance

Shares of NASDAQ IMNM opened at $21.44 on Monday. The firm has a 50-day simple moving average of $17.68 and a two-hundred day simple moving average of $12.73. The company has a market cap of $1.97 billion, a P/E ratio of -7.27 and a beta of 2.17. Immunome, Inc. has a 1 year low of $5.15 and a 1 year high of $25.30.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative return on equity of 76.50% and a negative net margin of 1,687.08%. As a group, equities research analysts expect that Immunome, Inc. will post -2.21 EPS for the current year.

Analysts Set New Price Targets

IMNM has been the subject of a number of recent research reports. Stephens raised their price target on shares of Immunome from $25.00 to $33.00 and gave the stock an “overweight” rating in a research report on Monday, November 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a report on Wednesday, October 8th. Evercore ISI upped their price target on shares of Immunome from $18.00 to $40.00 and gave the company an “outperform” rating in a report on Tuesday, December 16th. Truist Financial began coverage on Immunome in a report on Monday, December 1st. They set a “buy” rating and a $36.00 target price on the stock. Finally, Wall Street Zen upgraded Immunome from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Immunome currently has an average rating of “Moderate Buy” and a consensus target price of $30.09.

Hedge Funds Weigh In On Immunome

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Assetmark Inc. purchased a new position in Immunome in the third quarter valued at $39,000. BIT Capital GmbH acquired a new stake in Immunome in the third quarter valued at approximately $69,000. BNP Paribas Financial Markets grew its stake in shares of Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after purchasing an additional 2,909 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in Immunome in the third quarter valued at $76,000. Finally, Tower Research Capital LLC TRC lifted its holdings in Immunome by 121.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after buying an additional 3,802 shares during the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.